Artivion (AORT) Competitors $23.02 -0.12 (-0.50%) Closing price 04/15/2025 03:59 PM EasternExtended Trading$24.25 +1.24 (+5.37%) As of 04:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AORT vs. SLNO, IRTC, PRCT, NVST, TMDX, LIVN, ENOV, NVCR, LMAT, and CNMDShould you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), Envista (NVST), TransMedics Group (TMDX), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), LeMaitre Vascular (LMAT), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. Artivion vs. Soleno Therapeutics iRhythm Technologies PROCEPT BioRobotics Envista TransMedics Group LivaNova Enovis NovoCure LeMaitre Vascular CONMED Soleno Therapeutics (NASDAQ:SLNO) and Artivion (NYSE:AORT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Does the MarketBeat Community believe in SLNO or AORT? Soleno Therapeutics received 293 more outperform votes than Artivion when rated by MarketBeat users. However, 81.82% of users gave Artivion an outperform vote while only 72.56% of users gave Soleno Therapeutics an outperform vote. CompanyUnderperformOutperformSoleno TherapeuticsOutperform Votes32072.56% Underperform Votes12127.44% ArtivionOutperform Votes2781.82% Underperform Votes618.18% Is SLNO or AORT more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Artivion's net margin of -0.22%. Artivion's return on equity of 5.15% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -61.99% -55.21% Artivion -0.22%5.15%1.91% Do analysts recommend SLNO or AORT? Soleno Therapeutics presently has a consensus target price of $99.63, indicating a potential upside of 41.81%. Artivion has a consensus target price of $31.40, indicating a potential upside of 36.43%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Soleno Therapeutics is more favorable than Artivion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Artivion 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer SLNO or AORT? In the previous week, Soleno Therapeutics had 10 more articles in the media than Artivion. MarketBeat recorded 13 mentions for Soleno Therapeutics and 3 mentions for Artivion. Soleno Therapeutics' average media sentiment score of 1.07 beat Artivion's score of 0.71 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artivion 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of SLNO or AORT? 97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Artivion shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by company insiders. Comparatively, 8.1% of Artivion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, SLNO or AORT? Soleno Therapeutics has a beta of -2.29, meaning that its share price is 329% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Which has stronger valuation & earnings, SLNO or AORT? Artivion has higher revenue and earnings than Soleno Therapeutics. Artivion is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$38.99M-$4.26-16.49Artivion$388.54M2.53-$30.69M-$0.31-74.24 SummarySoleno Therapeutics beats Artivion on 11 of the 18 factors compared between the two stocks. Remove Ads Get Artivion News Delivered to You Automatically Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AORT vs. The Competition Export to ExcelMetricArtivionSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$982.49M$4.07B$5.33B$18.52BDividend YieldN/A39.49%5.11%4.22%P/E Ratio-1,150.7527.6321.6631.15Price / Sales2.5350.21373.3925.69Price / Cash36.7851.0838.1517.53Price / Book3.355.826.474.29Net Income-$30.69M$67.09M$3.20B$1.02B7 Day Performance-3.46%-0.17%2.86%-0.79%1 Month Performance-4.68%-3.20%-8.56%-6.88%1 Year Performance13.32%14.84%10.58%1.74% Artivion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AORTArtivion2.5719 of 5 stars$23.02-0.5%$31.40+36.4%+13.1%$982.49M$388.54M-1,150.751,300SLNOSoleno Therapeutics4.7834 of 5 stars$69.64+3.2%$99.63+43.1%+82.4%$3.19BN/A-20.9830Analyst ForecastGap DownHigh Trading VolumeIRTCiRhythm Technologies0.9178 of 5 stars$100.17-0.2%$119.73+19.5%-8.0%$3.15B$591.84M-27.521,790Positive NewsPRCTPROCEPT BioRobotics2.3992 of 5 stars$50.83-0.8%$94.29+85.5%+4.6%$2.79B$224.50M-26.07430Positive NewsGap DownHigh Trading VolumeNVSTEnvista4.3811 of 5 stars$15.27-1.4%$20.18+32.2%-21.0%$2.63B$2.51B-2.3512,700Analyst ForecastAnalyst RevisionNews CoveragePositive NewsGap DownTMDXTransMedics Group2.7684 of 5 stars$69.15+2.2%$122.70+77.4%-5.1%$2.33B$441.54M73.56210LIVNLivaNova3.561 of 5 stars$35.40-1.5%$61.17+72.8%-34.8%$1.92B$1.25B84.292,900Positive NewsHigh Trading VolumeENOVEnovis2.2227 of 5 stars$32.41-0.4%$58.50+80.5%-44.7%$1.85B$2.11B-14.806,800NVCRNovoCure3.335 of 5 stars$16.61+0.7%$35.80+115.5%+29.4%$1.83B$605.22M-11.861,320LMATLeMaitre Vascular3.0974 of 5 stars$79.39-0.5%$95.25+20.0%+31.3%$1.79B$219.86M43.38490Positive NewsHigh Trading VolumeCNMDCONMED4.7109 of 5 stars$55.34-1.6%$77.20+39.5%-35.5%$1.71B$1.31B13.054,100 Remove Ads Related Companies and Tools Related Companies Soleno Therapeutics Competitors iRhythm Technologies Competitors PROCEPT BioRobotics Competitors Envista Competitors TransMedics Group Competitors LivaNova Competitors Enovis Competitors NovoCure Competitors LeMaitre Vascular Competitors CONMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AORT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AORT Stock Free AORT Stock Alerts